Condition: Neuroendocrine Tumors · Sponsor: University Hospital, Basel, Switzerland
The goal of this monocentric, open-label, randomized-controlled, reader-blind clinical study is to assess the safety of the radiolabeled somatostatin receptor ligand, 61Cu-NODAGA-LM3, and its sensitivity in comparison to the standard of care, 68Ga-DOTATOC, for PET/CT imaging in patients with well differentiated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors.
This description comes directly from the study's public registry record.
Guillaume Nicolas, Dr. · + 41 61 328 66 82 · guillaume.nicolas@usb.ch
Damian Wild, Prof. Dr. Dr. · +41 61 32 86683 · damian.wild@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel, Department of Radiology and Nuclear Medicine | Basel, Canton of Basel-City, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06455358